The state of the fight: 

Moderna shared new Phase 2/3 data supporting the use of Spikevax in children under age 6.
  Pfizer will supply UNICEF with up to 4 million Paxlovid courses in 2022.
  Boosters of mRNA vaccines continued to offer strong protection against severe Covid-19 outcomes.   AUTHORIZED VACCINES

Moderna claimed clinical trial success for its vaccine in children ages 6 months to under 6 years. An interim analysis of Phase 2/3 results showed a “…

The state of the fight: 

Medicines Patent Pool sublicensed Pfizer’s Paxlovid to 35 generics manufacturers.
  Key WTO members reached a tentative agreement to waive some IP rights on Covid-19 vaccines.
  Moderna and Pfizer asked the U.S. FDA to authorize fourth doses of their respective jabs.   AUTHORIZED VACCINES

Medigen’s protein subunit vaccine (MVC-COV1901) offered similar safety and immunogenicity for adolescents as it did for adults, the Taipei-based…

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has dosed the first participant in a Phase 1 trial of a trio of mRNA-based vaccines against HIV, according to a press release Monday from the U.S. National Institutes of Health.

Manufactured by Moderna through a NIAID-backed contract, each of the three candidates in the mRNA-1574 vaccine program encodes for “different but highly related, stabilized proteins” of HIV, the press release said. The U.S.-based study seeks…


The state of the fight: 

Moderna pledged permanently to forgo enforcement of its Covid-19 vaccine patents for shots made “in or for” 92 LMICs.
  Aspen Pharmacare will market an Aspen-branded version of J&J’s vaccine in Africa.
  Fluvoxamine reduced the risk of Covid-19 hospitalization and clinical deterioration by 31% in a meta-analysis.   BOOSTERS

A WHO technical advisory group now “strongly supports urgent and broad access” to Covid-19 booster doses…

Moderna on Monday unveiled a sweeping global health strategy that includes an mRNA manufacturing facility in Kenya, an expanded pledge not to enforce patents on its Covid-19 shot in certain countries, and a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases. But the company also made clear it would pursue these objectives on its own terms, brushing aside activist demands that it share intellectual property with the WHO-led mRNA technology transfer hub in…

The state of the fight: 

Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
  South Africa’s Biovac partnered with nine development institutions to boost local vaccine manufacturing capacity.
  Eli Lilly’s arthritis drug Olumiant reduced the risk of death by 13% in hospitalized Covid-19 patients.   AUTHORIZED VACCINES

Pfizer/BioNTech’s Comirnaty is far less protective against infection in children ages…

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…

Moderna’s mRNA-based RSV vaccine candidate (mRNA-1345) has advanced to Phase 3 in adults age 60 and older, the Massachusetts-based company announced Tuesday. The U.S. FDA Fast Track-designated shot joins RSV candidates from J&J and Pfizer in late-stage trials. Numerous other vaccine makers are also in the race to bring the first RSV jab to market.

In other RSV news, Enanta Pharmaceuticals last week touted positive Phase 2 data on EDP-938, the Massachusetts-based firm’s N-protein…

The state of the fight: 

Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
  WHO named five additional African countries that will receive vaccine technology from the hub.
  Laboratorios Farmacéuticos Rovi inked a 10-year mRNA vaccine manufacturing extension with Moderna.   AUTHORIZED VACCINES

Medigen’s protein subunit…

BioNTech on Wednesday introduced the modular mRNA vaccine manufacturing platform it plans to deploy in Africa. But the fanfare was overshadowed by allegations—published last week in The BMJ—that a consultancy in the pay of the German company has sought to “undermine” a WHO-managed initiative for a multilateral mRNA technology transfer hub in South Africa. According to the BMJ article, the Malta-based Kenup Foundation circulated a report last year to South African government officials arguing…